Modulus develops engineered Natural Killer (NK) cell therapies optimized for autoimmune diseases, utilizing switch receptor arrays and best-in-class CARs to enhance safety and efficacy. The company addresses the limitations of existing CAR-T therapies, such as patient selection challenges and accessibility issues, by providing off-the-shelf solutions that eliminate the need for lymphodepletion.
Funding
$3.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing CAR-T therapies for autoimmune diseases face limitations, including challenges in patient selection due to toxicity risks, restricted patient access due to reliance on autologous products and specialized medical institutions, and the need for burdensome lymphodepletion. These factors limit the widespread applicability of cell therapies for autoimmune conditions.
Solution
Modulus develops off-the-shelf, engineered Natural Killer (NK) cell therapies designed to overcome the limitations of CAR-T therapies in treating autoimmune diseases. Their approach leverages the inherent safety profile of NK cells and eliminates the need for lymphodepletion, thereby increasing patient accessibility. Modulus utilizes best-in-class NK-specific CARs to eliminate autoreactive cells and switch receptor arrays to tune potency for different patient subsets and address heterogeneous disease mechanisms. The company employs rapid prototyping and generative design to accelerate cell therapy discovery, combining pre-made components to achieve complex design goals.
Target Audience
The primary target audience includes autoimmune patients underserved by current treatments, as well as medical institutions seeking safer and more accessible cell therapy options.
Features
- Off-the-shelf CAR-NK chassis leveraging the clinical safety record of NK cells
- Engineered receptors to overcome lymphodepletion requirements
- Best-in-class NK-specific CARs to eliminate autoreactive cells and enhance potency
- Switch receptor arrays to tune potency for different patient subsets and leverage multiple mechanisms of action
- Rapid prototyping and generative design for accelerated cell therapy discovery
- Platform for discovery of novel switch receptors for precise control of CAR-NK cell activity
- Custom CARs designed to enhance the persistence and cytotoxicity of NK cells